DVA Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of 5.05% compared to DaVita's net margin of 10.41%. DaVita's return on equity of 38.96% beat Encompass Health's return on equity of 18.4%.

DaVita has a consensus price target of $163.89, signalling upside risk potential of 17.15%. On the other hand Encompass Health has an analysts' consensus of $130.09 which suggests that it could grow by 9.07%. Given that DaVita has higher upside potential than Encompass Health, analysts believe DaVita is more attractive than Encompass Health.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.55% to investors and pays a quarterly dividend of $0.17 per share. DaVita pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.2B, which are larger than Encompass Health quarterly revenues of $1.5B. DaVita's net income of $162.9M is higher than Encompass Health's net income of $151.5M. Notably, DaVita's price-to-earnings ratio is 13.87x while Encompass Health's PE ratio is 24.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 2.21x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of 5.05% compared to DaVita's net margin of 0.21%. DaVita's return on equity of 38.96% beat LifeStance Health Group's return on equity of -2.48%.

DaVita has a consensus price target of $163.89, signalling upside risk potential of 17.15%. On the other hand LifeStance Health Group has an analysts' consensus of $8.86 which suggests that it could grow by 54.31%. Given that LifeStance Health Group has higher upside potential than DaVita, analysts believe LifeStance Health Group is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than LifeStance Health Group quarterly revenues of $333M. DaVita's net income of $162.9M is higher than LifeStance Health Group's net income of $709K. Notably, DaVita's price-to-earnings ratio is 13.87x while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 1.70x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

Surgery Partners has a net margin of 5.05% compared to DaVita's net margin of -4.86%. DaVita's return on equity of 38.96% beat Surgery Partners's return on equity of -5.45%.

DaVita has a consensus price target of $163.89, signalling upside risk potential of 17.15%. On the other hand Surgery Partners has an analysts' consensus of $31.55 which suggests that it could grow by 38.54%. Given that Surgery Partners has higher upside potential than DaVita, analysts believe Surgery Partners is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison Surgery Partners has a beta of 1.961, suggesting its more volatile than the S&P 500 by 96.073%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Surgery Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Surgery Partners pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than Surgery Partners quarterly revenues of $776M. DaVita's net income of $162.9M is higher than Surgery Partners's net income of -$37.7M. Notably, DaVita's price-to-earnings ratio is 13.87x while Surgery Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 0.91x for Surgery Partners. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 5.05% compared to DaVita's net margin of 6.97%. DaVita's return on equity of 38.96% beat US Physical Therapy's return on equity of 4.62%.

DaVita has a consensus price target of $163.89, signalling upside risk potential of 17.15%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 37.29%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 1.141, which suggesting that the stock is 14.065% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.783%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.29% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than US Physical Therapy quarterly revenues of $183.8M. DaVita's net income of $162.9M is higher than US Physical Therapy's net income of $12.8M. Notably, DaVita's price-to-earnings ratio is 13.87x while US Physical Therapy's PE ratio is 35.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 1.67x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.